Setmelanotide Guide
FDA-Approved MC4R Agonist for Genetic
Complete guide to Setmelanotide. Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm.
FDA-Approved MC4R Agonist for Genetic Obesity (IMCIVREE)
Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm Pharmaceuticals. Unlike GLP-1 medications that target appetite through incretin pathways, setmelanotide directly activates the MC4R pathway in the hypothalamus — the brain\'s primary appetite regulation center. It is specifically approved for rare genetic obesity disorders caused by POMC, PCSK1, or LEPR deficiency, with expansion studies ongoing for Bardet-Biedl syndrome and other genetic conditions. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Setmelanotide?
Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm Pharmaceuticals. Unlike GLP-1 medications that target appetite through incretin pathways, setmelanotide directly activates the MC4R pathway in the hypothalamus — the brain\'s primary appetite regulation center. It is specifically approved for rare genetic obesity disorders caused by POMC, PCSK1, or LEPR deficiency, with expansion studies ongoing for Bardet-Biedl syndrome and other genetic conditions.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
Clinical Data
Side Effects
Vital Protocol FAQs
Guide FAQs
Complete guide to Setmelanotide. Setmelanotide (brand name IMCIVREE) is an FDA-approved melanocortin 4 receptor (MC4R) agonist developed by Rhythm.
Yes. Shotlee supports tracking Setmelanotide doses, side effects, and health metrics. It is free to use.
Track Your Setmelanotide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
📚References & sources
Latest on Setmelanotide
Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market
While GLP-1R agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) dominate the obesity market, non-GLP-1R targets are poised for explosive growth. Sales for these alternatives are expected to surge almost 50-fold from $310m in 2026 to $15.5bn in 2031, driven by calcitonin receptor drugs. This diversification signals a reshaping of the $172.6bn obesity pharmaceutical landscape by 2031.
5 min read
Setmelanotide Potentially Enhances Obesity Drug Response in Hypothalamic Obesity
A recent study presented at ObesityWeek suggests that setmelanotide, when used alongside GLP-1 therapy, may lead to a substantial reduction in BMI for individuals with acquired hypothalamic obesity. The research indicates that restoring melanocortin-4 receptor pathway signaling could improve response to other anti-obesity treatments.
2 min read